Review



therapeutic continuous glucose monitoring devices  (Dexcom Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Dexcom Inc therapeutic continuous glucose monitoring devices
    International Funding of <t> Continuous Glucose Monitoring </t>
    Therapeutic Continuous Glucose Monitoring Devices, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/therapeutic+continuous+glucose+monitoring+devices/pmc05836597-1237-20-36?v=Dexcom+Inc
    Average 90 stars, based on 1 article reviews
    therapeutic continuous glucose monitoring devices - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment"

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    Journal: Ontario Health Technology Assessment Series

    doi:

    International Funding of Continuous Glucose Monitoring
    Figure Legend Snippet: International Funding of Continuous Glucose Monitoring

    Techniques Used: Diagnostic Assay

    Summary of Findings
    Figure Legend Snippet: Summary of Findings

    Techniques Used:

    Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a
    Figure Legend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a

    Techniques Used:

    Annual Costs of Continuous Glucose Monitoring and Insulin Pump a
    Figure Legend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a

    Techniques Used: Battery

    Sensitivity Analyses for Continuous Glucose Monitoring Model
    Figure Legend Snippet: Sensitivity Analyses for Continuous Glucose Monitoring Model

    Techniques Used:

    Government Expenses for the $920 Annual Grant to Purchase of Blood Glucose Test Strips Through the Ontario Monitoring for Health Program
    Figure Legend Snippet: Government Expenses for the $920 Annual Grant to Purchase of Blood Glucose Test Strips Through the Ontario Monitoring for Health Program

    Techniques Used:

    Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group
    Figure Legend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group

    Techniques Used:

    Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections
    Figure Legend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections

    Techniques Used:

    Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections
    Figure Legend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections

    Techniques Used:

    Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded
    Figure Legend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded

    Techniques Used:

    Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario
    Figure Legend Snippet: Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario

    Techniques Used:

    Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded
    Figure Legend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded

    Techniques Used:

    Estimated Annual Costs of Continuous Glucose Monitoring Devices With Cost-Reduction Scenarios
    Figure Legend Snippet: Estimated Annual Costs of Continuous Glucose Monitoring Devices With Cost-Reduction Scenarios

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Conservative Projection of a 20% Annual Increase a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Conservative Projection of a 20% Annual Increase a

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Funding for Insulin, Pump, Strips, and 75% of Sensor Costs
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Funding for Insulin, Pump, Strips, and 75% of Sensor Costs

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Conservative Projection of a 20% Annual Increase a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Conservative Projection of a 20% Annual Increase a

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Type 1 Diabetes Population a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Type 1 Diabetes Population a

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Population With Hypoglycemia Unawareness Using a Conservative Projection a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Population With Hypoglycemia Unawareness Using a Conservative Projection a

    Techniques Used:

    Net Budget Impact of Cost Reductions for Continuous Glucose Monitoring Devices
    Figure Legend Snippet: Net Budget Impact of Cost Reductions for Continuous Glucose Monitoring Devices

    Techniques Used:

    Continuous Glucose Monitoring Device Cost Reduction Scenarios
    Figure Legend Snippet: Continuous Glucose Monitoring Device Cost Reduction Scenarios

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Conservative Projection of a 20% Annual Increase, Device Cost Reduction by 30%, 20%, and 10%
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Conservative Projection of a 20% Annual Increase, Device Cost Reduction by 30%, 20%, and 10%

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Type 1 Diabetes Population, Device Cost Reduction by 30%, 20%, and 10%
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Type 1 Diabetes Population, Device Cost Reduction by 30%, 20%, and 10%

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 4, Device Cost Reduction by 30%, 20%, and 10%, Plus Government Funding a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 4, Device Cost Reduction by 30%, 20%, and 10%, Plus Government Funding a

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in Adoption of 40%
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in Adoption of 40%

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in CGM Adoption of 40%, Entire Type 1 Diabetes Population and Population With Hypoglycemia Unawareness
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in CGM Adoption of 40%, Entire Type 1 Diabetes Population and Population With Hypoglycemia Unawareness

    Techniques Used:

    Government Expenses for the $170 Annual Grant to Purchase Needles and Syringes for People With Type 1 Diabetes Age 65 Years and Older in Ontario
    Figure Legend Snippet: Government Expenses for the $170 Annual Grant to Purchase Needles and Syringes for People With Type 1 Diabetes Age 65 Years and Older in Ontario

    Techniques Used:

    Risk of Bias Among Randomized Controlled Trials for Comparison of Continuous Glucose Monitoring and Usual Care a
    Figure Legend Snippet: Risk of Bias Among Randomized Controlled Trials for Comparison of Continuous Glucose Monitoring and Usual Care a

    Techniques Used: Comparison

    Risk of Bias Among Observational Studies for Comparison of Continuous Glucose Monitoring and Usual Care a
    Figure Legend Snippet: Risk of Bias Among Observational Studies for Comparison of Continuous Glucose Monitoring and Usual Care a

    Techniques Used: Comparison


    Figure Legend Snippet:

    Techniques Used: Control


    Figure Legend Snippet:

    Techniques Used: Control

    GRADE Evidence Profile for Comparison of Continuous Glucose Monitoring and Usual Care
    Figure Legend Snippet: GRADE Evidence Profile for Comparison of Continuous Glucose Monitoring and Usual Care

    Techniques Used: Comparison

    Assessment of the Cost-Effectiveness of Continuous Glucose Monitoring
    Figure Legend Snippet: Assessment of the Cost-Effectiveness of Continuous Glucose Monitoring

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Population With Hypoglycemia Unawareness a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Population With Hypoglycemia Unawareness a

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Type 1 Diabetes Population a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Type 1 Diabetes Population a

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Population With Hypoglycemia Unawareness a
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Population With Hypoglycemia Unawareness a

    Techniques Used:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Population With Hypoglycemia Unawareness, Device Cost Reduction by 30%, 20%, and 10%
    Figure Legend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Population With Hypoglycemia Unawareness, Device Cost Reduction by 30%, 20%, and 10%

    Techniques Used:



    Similar Products

    therapeutic continuous glucose monitoring devices  (Dexcom Inc)
    90
    Dexcom Inc therapeutic continuous glucose monitoring devices
    International Funding of <t> Continuous Glucose Monitoring </t>
    Therapeutic Continuous Glucose Monitoring Devices, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/therapeutic+continuous+glucose+monitoring+devices/pmc05836597-1237-20-36?v=Dexcom+Inc
    Average 90 stars, based on 1 article reviews
    therapeutic continuous glucose monitoring devices - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    International Funding of Continuous Glucose Monitoring

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: International Funding of Continuous Glucose Monitoring

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: Diagnostic Assay

    Summary of Findings

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Summary of Findings

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Annual Costs of Continuous Glucose Monitoring and Insulin Pump a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: Battery

    Sensitivity Analyses for Continuous Glucose Monitoring Model

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Sensitivity Analyses for Continuous Glucose Monitoring Model

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Government Expenses for the $920 Annual Grant to Purchase of Blood Glucose Test Strips Through the Ontario Monitoring for Health Program

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Government Expenses for the $920 Annual Grant to Purchase of Blood Glucose Test Strips Through the Ontario Monitoring for Health Program

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Estimated Annual Costs of Continuous Glucose Monitoring Devices With Cost-Reduction Scenarios

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Estimated Annual Costs of Continuous Glucose Monitoring Devices With Cost-Reduction Scenarios

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Conservative Projection of a 20% Annual Increase a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Conservative Projection of a 20% Annual Increase a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Funding for Insulin, Pump, Strips, and 75% of Sensor Costs

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Funding for Insulin, Pump, Strips, and 75% of Sensor Costs

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Conservative Projection of a 20% Annual Increase a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Conservative Projection of a 20% Annual Increase a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Type 1 Diabetes Population a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Type 1 Diabetes Population a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Population With Hypoglycemia Unawareness Using a Conservative Projection a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Population With Hypoglycemia Unawareness Using a Conservative Projection a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Cost Reductions for Continuous Glucose Monitoring Devices

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Cost Reductions for Continuous Glucose Monitoring Devices

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Continuous Glucose Monitoring Device Cost Reduction Scenarios

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Continuous Glucose Monitoring Device Cost Reduction Scenarios

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Conservative Projection of a 20% Annual Increase, Device Cost Reduction by 30%, 20%, and 10%

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Conservative Projection of a 20% Annual Increase, Device Cost Reduction by 30%, 20%, and 10%

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Type 1 Diabetes Population, Device Cost Reduction by 30%, 20%, and 10%

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Type 1 Diabetes Population, Device Cost Reduction by 30%, 20%, and 10%

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 4, Device Cost Reduction by 30%, 20%, and 10%, Plus Government Funding a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 4, Device Cost Reduction by 30%, 20%, and 10%, Plus Government Funding a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in Adoption of 40%

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in Adoption of 40%

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in CGM Adoption of 40%, Entire Type 1 Diabetes Population and Population With Hypoglycemia Unawareness

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 5, Manufacturer's Scenario With an Annual Increase in CGM Adoption of 40%, Entire Type 1 Diabetes Population and Population With Hypoglycemia Unawareness

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Government Expenses for the $170 Annual Grant to Purchase Needles and Syringes for People With Type 1 Diabetes Age 65 Years and Older in Ontario

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Government Expenses for the $170 Annual Grant to Purchase Needles and Syringes for People With Type 1 Diabetes Age 65 Years and Older in Ontario

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Risk of Bias Among Randomized Controlled Trials for Comparison of Continuous Glucose Monitoring and Usual Care a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Risk of Bias Among Randomized Controlled Trials for Comparison of Continuous Glucose Monitoring and Usual Care a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: Comparison

    Risk of Bias Among Observational Studies for Comparison of Continuous Glucose Monitoring and Usual Care a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Risk of Bias Among Observational Studies for Comparison of Continuous Glucose Monitoring and Usual Care a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: Comparison

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet:

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: Control

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet:

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: Control

    GRADE Evidence Profile for Comparison of Continuous Glucose Monitoring and Usual Care

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: GRADE Evidence Profile for Comparison of Continuous Glucose Monitoring and Usual Care

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: Comparison

    Assessment of the Cost-Effectiveness of Continuous Glucose Monitoring

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Assessment of the Cost-Effectiveness of Continuous Glucose Monitoring

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Population With Hypoglycemia Unawareness a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Population With Hypoglycemia Unawareness a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Type 1 Diabetes Population a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Reference Case, Entire Type 1 Diabetes Population a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Population With Hypoglycemia Unawareness a

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario by Age Group—Scenario 2, Entire Population With Hypoglycemia Unawareness a

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques:

    Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Population With Hypoglycemia Unawareness, Device Cost Reduction by 30%, 20%, and 10%

    Journal: Ontario Health Technology Assessment Series

    Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

    doi:

    Figure Lengend Snippet: Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Entire Population With Hypoglycemia Unawareness, Device Cost Reduction by 30%, 20%, and 10%

    Article Snippet: 13 , 14 United States Some private insurance companies b Details differ depending on insurance company Medicare Funding for therapeutic continuous glucose monitoring devices Open in a separate window a Information was gathered in part from Dexcom (San Diego, California). b Blue Cross/Blue Shield, Aetna, Cigna, Humana, United Healthcare, Kaiser Permanente, Wellpoint.

    Techniques: